氟伏沙明对纤维肌痛综合征的疗效与安全性观察

摘要

目的:观察氟伏沙明治疗纤维肌痛综合征的疗效与安全性.方法:将60例门诊纤维肌痛综合征的患者,随机分为氟伏沙明组30例和安慰剂组30例.对照组治疗8周,氟伏沙明剂量50～150 mg/d,采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评价疗效.结果:54例完成了8周的临床观察,治疗后两组HAMD评分均有下降,氟伏沙明组评分明显低于安慰剂组.治疗后各个时间段评定(2、4、8周)两组的差异均具有统计学意义(P＜0.05).治疗8周后氟伏沙明组HAMA评分明显低于安慰剂组(6.7±4.5,11.7±8.3,P＜0.01),氟伏沙明组HAMD评分明显低于安慰剂组(10.5±6.5,19.8±6.9,P＜0.01).8周的治疗中氟伏沙明组仅出现轻度不良反应.结论:氟伏沙明治疗纤维肌痛综合征的疗效较好,具有良好的安全性和耐受性.%Objective: To observe the efficacy and safety of the treatment of fibromyalgia syndrome by fluvoxamine.Methods: 60 0utpatients with fibromyalgia syndrome were randomly divided into the Fluvoxamine group and placebo group, 30 cases in each group. The treatment lasted 8 weeks, evaluated by Hamilton Depression Rating Scale for Depression (HAMD) and Hamilton Anxiety Scale (HAMA). The dose of Fluvoxamine was 50～100 mg/d. Results: 54 patients completed the clinical observation of 8 weeks. After treatment, HAMD (24 items) scores of both groups decreased, and the score of the Fluvoxamine group was significantly lower than that of the placebo group. After treatment the assessments of all time (after 2, 4 weeks and 8 weeks) between the two groups had statistically significant (P＜0.05). After 8 weeks, HAMA score of Fluvoxamine group was significantly lower than that of the placebo group (6.7±4.5, 11.7±8.3, P＜0.01). HAMD score of fluvoxamine group was significantly lower than that of the placebo group (10.5±6.5, 19.8±6.9, P＜0.01). During the treatment of 8 weeks, only mild adverse reactions were discovered in the fluvoxamine group. Conclusion: The treatment of fibromyalgia syndrome by Fluvoxamine has a better effect, with good safety and tolerability.